Glenn DA, Pate V, Zee J, Walter EB, Denburg MR, Hogan S, Falk RJ, Mottl A, Layton JB. Influenza vaccine administration and effectiveness among children and adults with glomerular disease. Kidney Int Rep. 2024 Feb 9;9(2):257-65. doi: 10.1016/j.ekir.2023.10.031
Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C. Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2
Zhou X, Davenport E, Ouyang J, Hoke ME, Garbinsky D, Agarwal I, Krasa HB, Oberdhan D. Pooled data analysis of the long-term treatment effects of tolvaptan in ADPKD. Kidney Int Rep. 2022 Feb 19;7(5):1037-48. doi: 10.1016/j.ekir.2022.02.009
Ziyadeh NJ, Geldhof A, Noel W, Otero-Lobato M, Esslinger S, Chakravarty SD, Wang Y, Seeger JD. Post-approval safety surveillance study of golimumab in the treatment of rheumatic disease using a United States healthcare claims database. Clin Drug Invest. 2020 Nov;40(11):1021-40. doi: 10.1007/s40261-020-00959-7
Requena G, Ma L, Sturmer T, Layton JB, DiBello J. Association between an acute, drug-induced decrease in high-density lipoprotein cholesterol levels and risk of cardiovascular events. Clin Drug Invest. 2020 Aug;40:747-54. doi: 10.1007/s40261-020-00935-1
Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Hur P. Evaluation of the feasibility of a web-based survey to assess patient-reported symptom improvement and treatment satisfaction among patients with psoriatic arthritis receiving Secukinumab. Clin Drug Invest. 2019 Dec;39(12):1205-12. doi: 10.1007/s40261-019-00856-8
Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.
McKenna SP, Doward LC, Davey KM. The development and psychometric properties of the MSQOL: a migraine-specific quality-of-life instrument. Clin Drug Invest. 1998;15(5):413-23.